**Poster Session 06**

**The importance of survivorship issues in prostate cancer**

**Location:** Room Vienna (Hall B2, level 0)

**Chairs:**
- K. Mastris, Clayhall Ilford (GB)
- G. Morgia, San Giovanni La Punta (IT)
- M. Plata, Bogota (CO)

**Aims and objectives of this presentation**

New therapeutic strategies have produced a clear shift toward extended survival of patients with prostate cancer. Interestingly, the long-term consequences of treatments are still poorly understood in the general community. Understanding these better is the topic of this Survivorship session.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**Second primary tumors in prostate cancer: Data from two phase III trials**

**By:** Nabid A.\(^1\), Carrier N.\(^2\), Vigneault E.\(^3\), Martin A-G.\(^3\), Bahary J-P.\(^4\), Souhami L.\(^5\), Duclos M.\(^5\), Lemaire C.\(^5\), Brassard M-A.\(^7\), Vass S.\(^8\), Bahoric B.\(^9\), Archambault R.\(^10\), Vincent F.\(^11\), Nguyen-Huynh T-V.\(^4\)

**Institutes:**
- \(^1\)Centre Hospitalier Universitaire De Sherbrooke, Dept. of Radio-Oncology, Sherbrooke, Canada
- \(^2\)Centre Hospitalier Universitaire De Sherbrooke, Statistician, M.S.c., Sherbrooke, Canada
- \(^3\)Centre Hospitalier Universitaire De Montréal, Dept. of Radiation Oncology, Montréal, Canada
- \(^4\)Hopital Maisonneuve-Rosemont, Dept. of Radiation Oncology, Montréal, Canada
- \(^5\)Centre De Santé Et Services Sociaux De Chicoutimi, Dept. of Radiation Oncology, Chicoutimi, Canada
- \(^6\)Centre De Santé Et Services Sociaux De Chicoutimi, Dept. of Radiation Oncology, Chicoutimi, Canada
- \(^7\)Hopital Général Juif De Montréal, Dept. of Radiation Oncology, Montréal, Canada
- \(^8\)Centre Hospitalier Régional De Trois-Rivières, Dept. of Radiation Oncology, Trois-Rivières, Canada

---

**Secondary bladder cancer after anticancer therapy for prostate cancer; reduced comorbidity after androgen-deprivation therapy and increased comorbidity with smoking history**

**By:** Shiota M.\(^1\), Yokomizo A.\(^1\), Takeuchi A.\(^1\), Imada K.\(^1\), Kyoshima K.\(^1\), Inokuchi J.\(^1\), Tatsugami K.\(^1\), Ohga S.\(^2\), Nakamura K.\(^2\), Honda H.\(^2\), Naito S.\(^1\), Eto M.\(^1\)

**Institutes:**
- \(^1\)Kyushu University, Dept. of Urology, Fukuoka, Japan
- \(^2\)Kyushu University, Dept. of Clinical Radiology, Fukuoka, Japan

---

**Prophylactic irradiation of pelvic lymph-nodal area after prostatectomy does not increase the risk of second neoplasms: A single institution analysis of 1109 patients with 10 years follow-up**

**By:** Sini C.\(^2\), Cozzarini C.\(^3\), Fiorino C.\(^2\), Briganti A.\(^3\), Deantonii C.\(^3\), Fodor A.\(^3\), Fossati N.\(^2\), Gandaglia G.\(^3\), Noris Chiorda B.\(^3\), Perna L.\(^2\), Montorsi F.\(^3\), Calandrino R.\(^3\), Di Muzio N.\(^1\)

**Institutes:**
- \(^1\)San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy
- \(^2\)San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy
- \(^3\)San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

---

**What is the color of cancer?**

**By:** Tatli V., Ucer O., Muezzinoglu T.

**Institutes:**
- Celal Bayar University Faculty of Medicine, Dept. of Urology, Manisa, Turkey
Online support groups offer low-threshold backing for caregivers of patients with prostate cancer
By: Renner T., Maatz P., Muck T., Ihrig A., Huber J.
Institutes: Medical Faculty Carl Gustav Carus, Tu Dresden, Dept. of Urology, Dresden, Germany, University of Heidelberg, Dept. of General Internal Medicine and Psychosomatic, Heidelberg, Germany

When should patients undergo prostate biopsy? Decision analysis using differences in the health-related quality-of-life between pre-biopsy healthy men and patients with castration-resistant prostate cancer
Institutes: Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Dept. of Urology, Tokyo, Japan

Effect of prostate specific antigen parameters on global quality of life in prostate cancer patients during follow-up
Institutes: National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, National Cheng Kung University, Dept. of Public Health, Tainan, Taiwan

The correlation between retrograde leak point pressure and 24-hour pad weight for men with post prostatectomy incontinence
By: Solomon E., Malde S., Pakzad M., Hamid R., Shah J., Greenwell T.J., Ockrim J.
Institutes: University College London Hospitals, Dept. of Urology, London, United Kingdom

The impact of subsequent metastases on survival and medical costs in prostate cancer patients
By: Li T., Shore N.D., Mehra M., Saad M., Saadi R., Leblay G., Griffiths R.
Institutes: Janssen Global Services, Health Economics and Global Market Access, Raritan, United States of America, Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, United States of America, Janssen Global Services, Market Access Analytics and Policy, Raritan, United States of America, Janssen Global Services, Medical Affairs, Raritan, United States of America, Janssen Global Services, Global Oncology Strategy, Raritan, United States of America, Boston Health Economics, Health Services Consulting, Waltham, United States of America

Initial experience of an algorithm-based protocol for the community follow-up of men with stable prostate cancer
By: Goodall P., Little J., Robinson E., Trimble I., Cole O., Walton T.
Institutes: Nottingham City Hospital, Dept. of Urology, Nottingham, United Kingdom, Nottingham City Clinical Commissioning Group, Dept. of Clinical Commissioning, Nottingham, United Kingdom, Medical Specialist Group, Dept. of Urology, Guernsey, United Kingdom

Prospective evaluation of erectile function during four years after brachytherapy in men with low risk prostate cancer and baseline IIEF5 > 16
Institutes: Brest University Hospital, Dept. of Urology, Brest, France, Brest University Hospital, Dept. of Radiotherapy, Brest, France

Osteoporosis among men with prostate cancer during treatment with androgen deprivation therapy
By: Poulsen M.H., Frost M., Abrahamsen B., Gerke O., Walter S.
Institutes: Odense University Hospital, Dept. of Urology, Odense C, Denmark, Odense University Hospital, Dept. of Endocrinology and Metabolism, Odense C, Denmark, Holbæk Hospital, Dept. of Medicine and Endocrinology, Holbæk, Denmark, Odense University Hospital, Dept. of Nuclear Medicine, Odense C, Denmark
Morbidity, mortality and costs of treatment for locally advanced prostate cancer: A population-based analysis comparing radical prostatectomy and external beam radiation

By: Meyer C.¹, Feldman A.², Sanchez A.², Reznor G.¹, Hanske J.¹, Hanna N.¹, Kibel A.¹, Sammon J.³, Cole A.¹, Leow J.¹, Sun M.¹, Trinh Q.-D.¹

Institutes: ¹Brigham and Women’s Hospital, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Massachusetts General Hospital, Dept. of Urology, Boston, United States of America, ³Henry Ford Hospital, Vattikutti Urology Institute, Boston, United States of America